Genomics companies in agreement with Rhone-Poulenc Rorer:
This article was originally published in Clinica
Molecular Dynamics and Amersham Pharmacia Biotec are to supply drug company Rhone-Poulenc Rorer with microarray technology for measuring gene expression under an agreement between the three companies. Rhone-Poulenc will gain early access to integrated microarray systems in exchange for funding and technical expertise. The comparison of gene expression between normal and diseased genes is expected to improve the development of new diagnostics and therapeutics.
You may also be interested in...
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Among the largest gaps in safety data is non-clinical research on CBD use's effect on developing fetus and adolescent brain, in utero/lactational exposure, reproductive toxicity and the potential for a latency period before toxicity, says FDA neuroscientist Andrew Shen.
The templates from the US agency provide guidance to manufacturers developing antibody tests for clinical or at-home use.